NeoGenomics, Inc. Q1 FY2026 earnings call

Neogenomics is a pure-play oncology solutions company with a leading position in hematology. It has a portfolio of over 500 tests and is transforming its portfolio through product launches like RadarST entering the MRD market and the Pantracer family expansion. The clinical business is growing robustly, NGS growth far exceeds the market rate, and the commercial strategy focuses on the community setting to simplify oncology diagnostics.

Total revenue for Q1 was $186.7 million, up 11% year-over-year. Clinical revenue grew 14% year-over-year to $171 million, with NGS revenue up 26% and representing about a third of clinical revenue. Non-clinical revenue was $15.5 million, down 15% year-over-year. Adjusted EBITDA was $9 million, up 27% year-over-year, and the adjusted EBITDA margin expanded approximately 60 basis points.

2026 full-year revenue guidance revised to $797-803 million, up from $793-801 million. Q2 growth expected at ~9% y-o-y, Q3 9%-10%, Q4 above 10%. Adjusted EBITDA guidance maintained at $55-57 million, up ~27-31% y-o-y.

No detailed discussion of specific risks in the provided transcript, but refers to risks in SEC filings.

Q: David Westenberg focuses on NGS growth sustainability and AUP.

A: NGS growth is sustainable with Pantracer family and liquid biopsy, AUP driven by NGS mix and RCM initiatives.

Q: Tycho Peterson asks about guidance raise.

A: Guidance revised considering positives like clinical revenue growth and NGS, with potential upside in NGS portfolio.

Q: Puneet Soda asks about weather impact and NGS boundaries.

A: Weather impact anticipated and accounted for, NGS defined as therapy selection vertical for heme and solid tumors.